林扎戈利快速减少子宫肌瘤女性重度月经出血:PRIMROSE 1和2试验分析
该分析汇总PRIMROSE 1和2两项双盲安慰剂对照试验数据,纳入1012例子宫肌瘤伴重度月经出血女性,比较林扎戈利各剂量组与安慰剂组达到并维持临床显著出血减少的时间。林扎戈利多数剂量组中位起效时间<4周,200mg组仅3天,第4周达标并维持至第24周的累积发生率23.2%-68.1% vs 安慰剂7.8%。
要点
- 林扎戈利多数剂量组达到并维持临床显著出血减少的中位时间<4周(100mg单药除外)。
- 林扎戈利200mg联合或不联合激素反向添加治疗起效最快,中位时间仅3天。
- 第4周达标并维持至第24周累积发生率23.2%-68.1% vs 安慰剂7.8%。
核心结论
- 与安慰剂相比,林扎戈利可快速减少子宫肌瘤患者的临床显著重度月经出血。
- 林扎戈利为子宫肌瘤患者重度月经出血症状的快速管理提供了一种新的非侵入性治疗方法。
研究设计与样本
- 汇总PRIMROSE 1和PRIMROSE 2两项双盲、类似安慰剂对照试验数据,分别在美国和欧洲开展。
- 纳入1012例年龄≥18岁、超声确诊子宫肌瘤伴重度月经出血的女性,等比例随机分配至四个治疗组(林扎戈利100mg和200mg,联合或不联合由1mg雌二醇和0.5mg醋酸炔诺酮组成的激素反向添加治疗)和一个安慰剂组。
- 采用Kaplan-Meier图比较林扎戈利组与安慰剂组达到并维持临床显著重度月经出血减少至第24周的累积发生率,并校正种族和研究(PRIMROSE 1 vs PRIMROSE 2)混杂。
主要发现
- 林扎戈利各治疗组达到并维持临床显著重度月经出血减少的起效时间显著快于安慰剂组,多数林扎戈利剂量组中位时间<4周(100mg单药除外)。
- 林扎戈利200mg联合或不联合激素反向添加治疗起效最快,中位时间仅3天。
- 第4周达到并维持至第24周临床显著重度月经出血减少的累积发生率,四个林扎戈利治疗组为23.2%-68.1% vs 安慰剂组7.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the timing of the effect of linzagolix, an oral gonadotropin-releasing hormone receptor antagonist, on significant reduction in heavy menstrual bleeding (HMB) in women with uterine fibroids. DESIGN: The study used pooled data from PRIMROSE 1 and PRIMROSE 2, two double-blind, similar placebo-controlled trials of linzagolix in the United States and Europe, respectively. Eligible participants were randomized equally across four treatment arms (linzagolix 100 mg and 200 mg, with and without concomitant hormonal add-back therapy [ABT] consisting of 1-mg estradiol and 0.5-mg norethisterone acetate) and one placebo arm. The cumulative incidence of achieving clinically significant HMB reduction and maintaining it to week 24 was compared between the linzagolix arms and the placebo arm using the Kaplan-Meier plots adjusted for confounding by race and study (PRIMROSE 1 vs. PRIMROSE 2). SUBJECTS: The PRIMROSE trials randomized 1,012 women aged ≥18 years with ultrasound-confirmed uterine fibroids and HMB. INTERVENTION: Linzagolix (100 mg and 200 mg, with and without hormonal ABT) vs. placebo. MAIN OUTCOME MEASURES: The main outcome of this analysis was the time to achievement of clinically significant HMB reduction and its maintenance up to week 24. RESULTS: The onset of action in achieving and maintaining clinically significant HMB reduction was significantly more rapid for the linzagolix treatment arms than for the placebo arm, with a median time of <4 weeks for most linzagolix doses (except 100 mg alone). The fastest onset was seen with linzagolix 200 mg with or without ABT doses, with a median time of only 3 days. The cumulative incidence of achieving clinically significant HMB reduction by week 4 and maintaining it to week 24 was also significantly higher for the linzagolix treatment arms than for the placebo arm. Specifically, across four linzagolix treatment arms, 23.2%-68.1% achieved clinically significant HMB reduction by week 4 and maintained it to week 24 vs. 7.8% for the placebo arm. CONCLUSION: Linzagolix was associated with a quick effect on reducing clinically significant HMB compared with placebo. Linzagolix, thus, offers a novel noninvasive treatment approach for the rapid management of HMB symptoms in patients with uterine fibroids.
引用
- Donnez J, Becker CM, Mangler M, et al. Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE 1 and 2 trials. Fertil Steril. 2025. PMID: 39755138. doi:10.1016/j.fertnstert.2024.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。